Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population

Ahmed Al Hinai, Upender Krishen Wali, Tayseer Abdul Rasool, Syed G. Rizvi

Research output: Contribution to journalArticle

Abstract

PURPOSE: The purpose of this study was to evaluate the outcome of intravitreal (IVT) triamcinolone in diabetic macular edema (DME). MATERIALS AND METHODS: A retrospective study of 42 eyes diagnosed clinically and supported with optical coherence tomography (OCT), with DME of more than 300 μm in thickness. All eyes were injected with a single IVT injection of preservative free triamcinolone acetonide (TA) with dose of 4 mg. Patients were subjected to visual acuity (VA) and OCT on each follow-up visit which was continued for 6 months. The total number of IVT injections given was 48. Six eyes had a repeat injection. None of the eyes had any other IVT injection within 6 weeks of TA. Twenty-one eyes were pseudophakic. RESULTS: Mean age of the patients was 58.8 years. The mean central subfield thickness (CST) at baseline was 504.6 μm. At 6 weeks, the mean CST dropped by 183.6 μm (P < 0.00001). At 6-month follow-up, the mean CST had increased by 74.6 μm from 6 weeks level; however, the 6-month mean CST was 109 μ less than mean baseline thickness (P < 0.0005). The mean baseline VA was 0.80 LogMAR units. At 6 weeks, the mean VA dropped by 0.01 LogMAR. At 6 months, VA improved by 0.02 LogMAR units from baseline. Overall, VA improved in 47% eyes, dropped from baseline in 35% eyes, and remained unchanged in 18% eyes. CONCLUSION: Triamcinolone acetonide is a safe, effective, and promising therapy in DME.

Original languageEnglish
Pages (from-to)177-183
Number of pages7
JournalOman Journal of Ophthalmology
Volume10
Issue number3
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Triamcinolone Acetonide
Macular Edema
Visual Acuity
Population
Intravitreal Injections
Optical Coherence Tomography
Therapeutics
Triamcinolone
Retrospective Studies
Injections

Keywords

  • Diabetic macular edema
  • optical coherence tomography
  • triamcinolone acetonide
  • visual acuity

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population. / Al Hinai, Ahmed; Wali, Upender Krishen; Rasool, Tayseer Abdul; Rizvi, Syed G.

In: Oman Journal of Ophthalmology, Vol. 10, No. 3, 01.09.2017, p. 177-183.

Research output: Contribution to journalArticle

@article{54ef88a4dba8440ab642daf8c952b290,
title = "Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population",
abstract = "PURPOSE: The purpose of this study was to evaluate the outcome of intravitreal (IVT) triamcinolone in diabetic macular edema (DME). MATERIALS AND METHODS: A retrospective study of 42 eyes diagnosed clinically and supported with optical coherence tomography (OCT), with DME of more than 300 μm in thickness. All eyes were injected with a single IVT injection of preservative free triamcinolone acetonide (TA) with dose of 4 mg. Patients were subjected to visual acuity (VA) and OCT on each follow-up visit which was continued for 6 months. The total number of IVT injections given was 48. Six eyes had a repeat injection. None of the eyes had any other IVT injection within 6 weeks of TA. Twenty-one eyes were pseudophakic. RESULTS: Mean age of the patients was 58.8 years. The mean central subfield thickness (CST) at baseline was 504.6 μm. At 6 weeks, the mean CST dropped by 183.6 μm (P < 0.00001). At 6-month follow-up, the mean CST had increased by 74.6 μm from 6 weeks level; however, the 6-month mean CST was 109 μ less than mean baseline thickness (P < 0.0005). The mean baseline VA was 0.80 LogMAR units. At 6 weeks, the mean VA dropped by 0.01 LogMAR. At 6 months, VA improved by 0.02 LogMAR units from baseline. Overall, VA improved in 47{\%} eyes, dropped from baseline in 35{\%} eyes, and remained unchanged in 18{\%} eyes. CONCLUSION: Triamcinolone acetonide is a safe, effective, and promising therapy in DME.",
keywords = "Diabetic macular edema, optical coherence tomography, triamcinolone acetonide, visual acuity",
author = "{Al Hinai}, Ahmed and Wali, {Upender Krishen} and Rasool, {Tayseer Abdul} and Rizvi, {Syed G.}",
year = "2017",
month = "9",
day = "1",
doi = "10.4103/ojo.OJO_173_2016",
language = "English",
volume = "10",
pages = "177--183",
journal = "Oman Journal of Ophthalmology",
issn = "0974-620X",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "3",

}

TY - JOUR

T1 - Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population

AU - Al Hinai, Ahmed

AU - Wali, Upender Krishen

AU - Rasool, Tayseer Abdul

AU - Rizvi, Syed G.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - PURPOSE: The purpose of this study was to evaluate the outcome of intravitreal (IVT) triamcinolone in diabetic macular edema (DME). MATERIALS AND METHODS: A retrospective study of 42 eyes diagnosed clinically and supported with optical coherence tomography (OCT), with DME of more than 300 μm in thickness. All eyes were injected with a single IVT injection of preservative free triamcinolone acetonide (TA) with dose of 4 mg. Patients were subjected to visual acuity (VA) and OCT on each follow-up visit which was continued for 6 months. The total number of IVT injections given was 48. Six eyes had a repeat injection. None of the eyes had any other IVT injection within 6 weeks of TA. Twenty-one eyes were pseudophakic. RESULTS: Mean age of the patients was 58.8 years. The mean central subfield thickness (CST) at baseline was 504.6 μm. At 6 weeks, the mean CST dropped by 183.6 μm (P < 0.00001). At 6-month follow-up, the mean CST had increased by 74.6 μm from 6 weeks level; however, the 6-month mean CST was 109 μ less than mean baseline thickness (P < 0.0005). The mean baseline VA was 0.80 LogMAR units. At 6 weeks, the mean VA dropped by 0.01 LogMAR. At 6 months, VA improved by 0.02 LogMAR units from baseline. Overall, VA improved in 47% eyes, dropped from baseline in 35% eyes, and remained unchanged in 18% eyes. CONCLUSION: Triamcinolone acetonide is a safe, effective, and promising therapy in DME.

AB - PURPOSE: The purpose of this study was to evaluate the outcome of intravitreal (IVT) triamcinolone in diabetic macular edema (DME). MATERIALS AND METHODS: A retrospective study of 42 eyes diagnosed clinically and supported with optical coherence tomography (OCT), with DME of more than 300 μm in thickness. All eyes were injected with a single IVT injection of preservative free triamcinolone acetonide (TA) with dose of 4 mg. Patients were subjected to visual acuity (VA) and OCT on each follow-up visit which was continued for 6 months. The total number of IVT injections given was 48. Six eyes had a repeat injection. None of the eyes had any other IVT injection within 6 weeks of TA. Twenty-one eyes were pseudophakic. RESULTS: Mean age of the patients was 58.8 years. The mean central subfield thickness (CST) at baseline was 504.6 μm. At 6 weeks, the mean CST dropped by 183.6 μm (P < 0.00001). At 6-month follow-up, the mean CST had increased by 74.6 μm from 6 weeks level; however, the 6-month mean CST was 109 μ less than mean baseline thickness (P < 0.0005). The mean baseline VA was 0.80 LogMAR units. At 6 weeks, the mean VA dropped by 0.01 LogMAR. At 6 months, VA improved by 0.02 LogMAR units from baseline. Overall, VA improved in 47% eyes, dropped from baseline in 35% eyes, and remained unchanged in 18% eyes. CONCLUSION: Triamcinolone acetonide is a safe, effective, and promising therapy in DME.

KW - Diabetic macular edema

KW - optical coherence tomography

KW - triamcinolone acetonide

KW - visual acuity

UR - http://www.scopus.com/inward/record.url?scp=85031995918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031995918&partnerID=8YFLogxK

U2 - 10.4103/ojo.OJO_173_2016

DO - 10.4103/ojo.OJO_173_2016

M3 - Article

VL - 10

SP - 177

EP - 183

JO - Oman Journal of Ophthalmology

JF - Oman Journal of Ophthalmology

SN - 0974-620X

IS - 3

ER -